Semaglutide Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on Semaglutide for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

Semaglutide is classified as a Long-acting GLP-1 receptor agonist (acylated, albumin-binding). Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | Semaglutide | | --- | --- | | Classification | Long-acting GLP-1 receptor agonist (acylated, albumin-binding) | | Serum half-life | Terminal half-life of approximately 165–184 hours (~7 days) in published human PK studies — supports once-weekly subcutaneous dosing. | | Tmax | Tmax of 1–3 days post-injection; steady-state reached after ~4–5 weeks of weekly dosing. | | Validated routes | Subcutaneous (research and clinical) and oral (clinical, with SNAC absorption enhancer) — oral bioavailability remains very low (<2%). | | Bioavailability | Subcutaneous bioavailability ~89% in published PK literature; oral ~1%. | | Clearance | Cleared via proteolytic degradation and renal elimination of fragments; no dose adjustment required in mild–moderate renal impairment in published data. |

Serum Half-Life

Terminal half-life of approximately 165–184 hours (~7 days) in published human PK studies — supports once-weekly subcutaneous dosing.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For Semaglutide, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of 1–3 days post-injection; steady-state reached after ~4–5 weeks of weekly dosing.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous (research and clinical) and oral (clinical, with SNAC absorption enhancer) — oral bioavailability remains very low (<2%).

Bioavailability across routes: Subcutaneous bioavailability ~89% in published PK literature; oral ~1%.

Clearance & Metabolism

Cleared via proteolytic degradation and renal elimination of fragments; no dose adjustment required in mild–moderate renal impairment in published data.

Key Pharmacokinetic Takeaways

• Among the longest half-lives in the GLP-1 class due to fatty-acid albumin-binding chemistry
• Weekly dosing achieves stable plasma exposure; missed doses are partially buffered by the long half-life
• Steady-state takes ~4–5 weeks — pharmacodynamic endpoints should account for this ramp
• Pharmacokinetic profile underpins its use as the reference GLP-1 in head-to-head research

Frequently Asked Questions

What is the half-life of Semaglutide? Terminal half-life of approximately 165–184 hours (~7 days) in published human PK studies — supports once-weekly subcutaneous dosing.

How quickly does Semaglutide reach peak concentration? Tmax of 1–3 days post-injection; steady-state reached after ~4–5 weeks of weekly dosing.

Which routes of administration are validated in published research? Subcutaneous (research and clinical) and oral (clinical, with SNAC absorption enhancer) — oral bioavailability remains very low (<2%).

Does Semaglutide accumulate with repeat dosing? Cleared via proteolytic degradation and renal elimination of fragments; no dose adjustment required in mild–moderate renal impairment in published data. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for Semaglutide? Subcutaneous bioavailability ~89% in published PK literature; oral ~1%.

Related Research

• Reconstitution & storage protocols — see the Semaglutide reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the Semaglutide dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the Semaglutide mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*